Evogene (EVGN) Receivables (2016 - 2025)
Evogene (EVGN) has disclosed Receivables for 10 consecutive years, with $1.9 million as the latest value for Q4 2025.
- Quarterly Receivables rose 64.37% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, up 64.37% year-over-year, with the annual reading at $1.9 million for FY2025, 64.37% up from the prior year.
- Receivables hit $1.9 million in Q4 2025 for Evogene, up from $1.1 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $3.3 million in Q4 2023 to a low of $1.1 million in Q4 2024.
- Historically, Receivables has averaged $2.2 million across 5 years, with a median of $1.9 million in 2025.
- Biggest five-year swings in Receivables: surged 81.97% in 2023 and later tumbled 65.62% in 2024.
- Year by year, Receivables stood at $2.9 million in 2021, then crashed by 37.59% to $1.8 million in 2022, then soared by 81.97% to $3.3 million in 2023, then crashed by 65.62% to $1.1 million in 2024, then soared by 64.37% to $1.9 million in 2025.
- Business Quant data shows Receivables for EVGN at $1.9 million in Q4 2025, $1.1 million in Q4 2024, and $3.3 million in Q4 2023.